Login to Your Account



Pharma: Clinic Roundup


Wednesday, May 23, 2012
• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said results from the pivotal Phase III GEMINI trial showed that, after six weeks of induction therapy, 47. 1 percent of patients with moderately to severely active ulcerative colitis who received gut-selective monoclonal antibody vedolizumab experienced clinical response vs. 25.5 percent in the placebo group (p < 0.0001).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription